There is, however, the considerable risk of inducing anti-ADAMTS13 alloantibodies during treatment (like in hemophiliacs with FVIII inhibitors), which will cause major problems, as neither plasma infusion nor PEX or rADAMTS13 will be sufficient to treat acute bouts of TTP. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.